IMMP News and Press, Immutep Limited From 06/27/24

2024-06-27 08:00:12 ET Joel Beatty from Robert W. Baird issued a price target of $6.00 for IMMP on 2024-06-27 06:42:00. The adjusted price target was set to $6.00. At the time of the announcement, IMMP was trading at $2.77. The overall price target consensus is at $10.00...

Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today anno...

2024-06-05 14:32:23 ET More on Immutep Immutep: Realizing The Expected Catalysts, With More To Come Immutep reports promising efti/Keytruda data for head and neck cancer Seeking Alpha’s Quant Rating on Immutep Historical earnings data for Immutep ...

Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce the successful completion of its institutional placement ( Placement ) and the institutional component ( Institutional Enti...

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to add...

2024-05-17 08:00:11 ET Naureen Quibria from Capital One Financial issued a price target of $10.00 for IMMP on 2024-05-17 07:10:00. The adjusted price target was set to $10.00. At the time of the announcement, IMMP was trading at $2.92. IMMP currently trades -24.74% versu...

Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxel Ongoing complete response has been maintained since the patient started treatment with efti m...

Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of...

2024-05-01 12:39:01 ET Summary Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint, for various tumor types. The company's pipeline includes eftilagimod, which has shown promising response rates in thoracic malignancies. Immutep shoul...

Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patient reporting a complete response (complete disappearance of all lesions), and a 100% disease ...